logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

eTNBC: add-on adjuvant capecitabine extends survival in meta-analysis

Both DFS and OS improve up to 35% across 7 trials with 1600 patients.